2B30.F XERIS BIOPH.HOL. DL-0001
- Market cap
- EUR 2.55B
- P/E
- -
- P/B
- 58.29x
- ROE
- -48.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 2B30.F undervalued?
Graham numberThe Graham number of XERIS BIOPH.HOL. DL-0001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
XERIS BIOPH.HOL. DL-0001 fundamental analysis
No fundamental analysis for XERIS BIOPH.HOL. DL-0001 yet.
XERIS BIOPH.HOL. DL-0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About XERIS BIOPH.HOL. DL-0001
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhib…
Full company profileXERIS BIOPH.HOL. DL-0001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
XERIS BIOPH.HOL. DL-0001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 49.6M | 110M | 164M | 203M | 292M | 377M |
| Gross Profit | 36.3M | 87.6M | 135M | 166M | 249M | 329M |
| Operating Income | -115M | -81.9M | -44.0M | -33.6M | 24.9M | 40.0M |
| EBITDA | - | -69.3M | -23.7M | -14.0M | 42.3M | 16.5M |
| Net Income | -123M | -94.7M | -62.3M | -54.8M | 554K | -23.4M |
| EPS | -0.98 | -0.69 | -0.45 | -0.37 | 0.00 | -0.13 |
| Balance Sheet | ||||||
| Total Assets | 304M | 345M | 323M | 323M | 384M | 423M |
| Total Liabilities | 209M | 299M | 329M | 353M | 370M | 374M |
| Shareholders' Equity | 95.2M | 45.2M | -6.78M | -29.6M | 13.7M | 48.8M |
| Cash & Short-term Investments | 67.3M | 122M | 67.4M | 71.6M | 111M | 131M |
| Cash Flow | ||||||
| Operating Cash Flow | -95.5M | -103M | -47.0M | -37.0M | 28.6M | 71.5M |
| Capital Expenditure | 1.09M | 524K | 2.26M | 868K | 696K | 924K |
| Free Cash Flow | -96.6M | -103M | -49.3M | -37.8M | 27.9M | 70.5M |
| Ratios | ||||||
| ROE | -128.9% | -209.5% | - | - | 4.0% | -48.0% |
| ROA | -40.3% | -27.5% | -19.3% | -17.0% | 0.1% | -5.5% |
| Net Profit Margin | -247.5% | -85.9% | -38.0% | -27.0% | 0.2% | -6.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
XERIS BIOPH.HOL. DL-0001 dividends
XERIS BIOPH.HOL. DL-0001 has not paid dividends in the last 5 fiscal years.
Who owns XERIS BIOPH.HOL. DL-0001
- Insiders 3.00%
- Institutions 63.20%
- Public & others 33.80%
- Shares outstanding 183M
- Free float 177M
XERIS BIOPH.HOL. DL-0001 company profile
- Company name
- XERIS BIOPH.HOL. DL-0001
- Ticker
- 2B30.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 435
- Fiscal year end
- December
- Address
- 1375 West Fulton Street, Chicago, IL, United States, 60607
- Phone
- 844 445 5704
- Website
- xerispharma.com
About XERIS BIOPH.HOL. DL-0001
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
XERIS BIOPH.HOL. DL-0001 management
5- Mr. John P. ShannonChairman & CEO · born 1962
- Mr. Kevin McCullochPresident & COO · born 1964
- Mr. Steven M. PieperChief Financial Officer · born 1977
- Ms. Beth P. Hecht J.D.Chief Legal Officer & Corporate Secretary · born 1964
- Dr. Anh T. Nguyen M.B.A., M.D.Chief Medical Officer · born 1975